ArticleCVIR endovascular2025
Controlled expansion stent grafts versus legacy stent grafts for transjugular intrahepatic portosystemic shunt: a single-centre retrospective study on the incidence of hepatic encephalopathy.
Article in CVIR endovascular, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk factors for hepatic encephalopathy in patients following transjugular intrahepatic portosystemic shunt: a meta-analysis and systematic review.BMC surgery · 2026Pooled it
- Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Using Dedicated versus Generic Stent-Grafts in Cirrhotic Patients.Cardiovascular and interventional radiology · 2026Article
- Fluoroscopic quantification of early in vivo expansion of VIATORR controlled expansion stent-grafts after TIPS: hemodynamic and clinical implications.Abdominal radiology (New York) · 2026Article
- Letter to the Editor: Beyond the liver - integrating emerging predictors in hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.World journal of radiology · 2026Article
- Expandable Constrained Transjugular Intrahepatic Portosystemic Shunt: An Individualised Approach for High-Risk Patients?Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAssess incidence of hepatic encephalopathy (HE) after transjugular intrahepatic portosystemic shunt (TIPS) in patients treated with 8-10 mm Controlled Expansion diameter VIATORR® (VCX) versus 10 mm diameter first-generation VIATORR® (Legacy) stent-grafts. MATERIALS AND
methodsSingle-centre retrospective study (January 2015 to March 2024), including 132 adult patients with cirrhosis treated with TIPS due to complications of portal hypertension. Outcomes included post-TIPS new onset overt HE, ascites response, re-bleeding, mortality and portal pressure gradient (PPG) before and after TIPS. Comparisons used Chi square and Fisher´s exact test for categorical variables and Student´s t test or Mann-Whitney test for quantitative variables.
resultsIndication for TIPS was refractory ascites (n = 82) and variceal bleeding (n = 50). The VCX group (n = 85) and the Legacy group (n = 47) had similar new onset overt HE: 37% (31/85) vs 43% (20/47), respectively (p = 0.31); mortality rates (34% [29/85]) vs 39% [18/47], respectively, p = 0.57) and re-bleeding (17% [6/35] vs 20% [3/15], respectively, p = 1.00). Median PPG reduction after TIPS was 10 mmHg (7 - 13) in the VCX group and 12 mmHg (9 - 15) in the Legacy group (p = 0.02). Subgroup analysis revealed post TIPS overt HE rate of 38% (19/50) in the VCX group vs 53% (17/32) in the Legacy group (p = 0.13), with refractory ascites as an indication. Shunt dysfunction rate was 7% (6/85) in the VCX group (stent thrombosis n = 6, stenosis or malpositioning n = 0) and 0% (0/47) in the Legacy group (p = 0.09).
conclusionVCX stent grafts induce an immediate lower PPG reduction, which might lead to more stent dysfunctions, but also to a reduction in post-TIPS HE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.